ALKERMES | ALKS - Loan Capital



ALKERMES reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 0 0 Mar/2025
Amgen USD 53.76B 253M Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
BioMarin Pharmaceutical USD 596.16M 512K Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
Ionis Pharmaceuticals USD 625.49M 625.22M Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Malin Corporation EUR 0 0 Dec/2024
Merck USD 33.97B 484M Jun/2025
Neurocrine Biosciences USD 0 0 Dec/2024
Otsuka Holdings JPY 153.76B 27.32B Jun/2025
Pfizer USD 57.5B 137M Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024